National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ozenoxacin (Dubine®) 10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/11/2018
Rapid review completed 13/12/2018
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.